CytoAgents Overview

  • Founded
  • 2018
Founded
  • Status
  • Private
  • Employees
  • 13
Employees
  • Latest Deal Type
  • Series A
  • Latest Deal Amount
  • $25M
Latest Deal Amount
  • Investors
  • 9

CytoAgents General Information

Description

Developer of innovative pharmaceutical drugs designed to treat cytokine release syndrome. The company's drugs develop a broadly accessible treatment for multiple indications of high unmet need, including oncology CAR-T cell therapy, COVID-19 and respiratory epidemics, enabling physicians to effectively patients suffering from CRS through a novel approach by calming the natural immune response to a multi-organ disease.

Contact Information

Website
www.cytoagents.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Drug Delivery
Biotechnology
Primary Office
  • 100 South Commons
  • Suite 102
  • Pittsburgh, PA 15212
  • United States

CytoAgents Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

CytoAgents Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Early Stage VC (Series A) $25M 0000 Completed Generating Revenue
6. Early Stage VC 11-Aug-2021 00000 00.000 Completed Generating Revenue
5. Accelerator/Incubator 04-Apr-2021 00000 00.000 Completed Generating Revenue
4. Grant 10-Mar-2021 00.00 00.000 Completed Generating Revenue
3. Early Stage VC 20-Jan-2021 00.00 00.000 Completed Generating Revenue
2. Early Stage VC 07-Jul-2020 $250K $3.75M Completed Generating Revenue
1. Seed Round 17-Jan-2020 $3.5M $3.5M Completed Generating Revenue
To view CytoAgents’s complete valuation and funding history, request access »

CytoAgents Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of innovative pharmaceutical drugs designed to treat cytokine release syndrome. The company's drugs develop a
Drug Discovery
Pittsburgh, PA
13 As of 2022
0000
000000 0 0000

0000000

itation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehende
0000 000000000
Waltham, MA
000 As of 0000
00000
000000 - 000 00000

0000000

or sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna
0000 000000000
Boston, MA
0 As of 0000
00000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

CytoAgents Competitors (43)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Apellis Formerly VC-backed Waltham, MA 000 00000 000000 - 000 00000
0000000 0000000000 Formerly VC-backed Boston, MA 0 00000 000000000 00000
00000 000000000000 Formerly VC-backed Cambridge, MA 00 00000 000000 - 000 00000
00000000 Formerly VC-backed Waltham, MA 00 00000 000000&0 00000
000000 00000000000 Formerly VC-backed San Diego, CA 00 00000 000000 - 000 00000
You’re viewing 5 of 43 competitors. Get the full list »

CytoAgents Patents

  • 1

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 000

    Granted

  • 1

    Pending

  • 000

    Expiring in next 12 mo

CytoAgents Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210244746-A1 Compositions and methods for treating coronavirus infections Pending 12-Feb-2020 00000000000

CytoAgents Executive Team (6)

Name Title Board Seat Contact Info
Teresa Whalen Founder, Chief Executive Officer, President & Board Member
Roy Prieb Chief Financial Officer
Jodi Craigo Chief Scientific Officer
Todd Lorenz MD Chief Medical Officer
James Nolan Head of Business Development
You’re viewing 5 of 6 executive team members. Get the full list »

CytoAgents Board Members (5)

Name Representing Role Since
Anthony McCarley CytoAgents Board Member 000 0000
Catherine Mott BlueTree Allied Angels Board Member 000 0000
John Friedman JD Self Board Member 000 0000
Stanley Marks MD Self Board Member 000 0000
Teresa Whalen CytoAgents Founder, Chief Executive Officer, President & Board Member 000 0000
To view CytoAgents’s complete board members history, request access »

CytoAgents Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

CytoAgents Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
AlphaLab Health Accelerator/Incubator Minority 000 0000 000000 0
National Institutes of Health Government 000 0000 000000 0
Richard King Mellon Foundation Limited Partner Minority 000 0000 000000 0
BlueTree Allied Angels Angel Group Minority 000 0000 000000 0
Boston Harbor Angels Angel Group Minority 000 0000 000000 0
You’re viewing 5 of 9 investors. Get the full list »

Ready to get started?

Request a free trial